Contact PR

To use this feature, join Babbler easily !


Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up


Nice to see you again !

Press release

Toujeo® reduced risk of severe low blood sugar compared to insulin glargine
timer minutes reading time minute reading time

Copy link

Click to get original image size

VIENNA - February 14, 2018 - With the continued evolution in diabetes care and a growing understanding of today’s insulin options, Sanofi is pleased to share new real-world evidence results which showed that Toujeo® (insulin glargine 300 Units/mL) significantly reduced the risk of severe low blood sugar (hypoglycemia) events compared to the long-acting insulins, insulin glargine 100 Units/mL (Lantus) and insulin detemir. These data are being presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Vienna, Austria.

Hit the download button to get the document.

  • Health & Medicine
  • Medicine
  • Men's Health
  • Women's Health
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine
  • Men's Health